Deb Kaushik Dilip, Sarda Kanchan
Embryonic Stem Cell Program, Manipal Institute of Regenerative Medicine, #10 Service Road, Domlur, Bangalore 560071, India.
J Transl Med. 2008 Jan 29;6:7. doi: 10.1186/1479-5876-6-7.
Human embryonic stem cells (hESCs) have been extensively discussed in public and scientific communities for their potential in treating diseases and injuries. However, not much has been achieved in turning them into safe therapeutic agents. The hurdles in transforming hESCs to therapies start right with the way these cells are derived and maintained in the laboratory, and goes up-to clinical complications related to need for patient specific cell lines, gender specific aspects, age of the cells, and several post transplantation uncertainties. The different types of cells derived through directed differentiation of hESC and used successfully in animal disease and injury models are described briefly. This review gives a brief outlook on the present and the future of hESC based therapies, and talks about the technological advances required for a safe transition from laboratory to clinic.
人类胚胎干细胞（hESCs）因其在治疗疾病和损伤方面的潜力，已在公众和科学界得到广泛讨论。然而，将它们转化为安全的治疗药物方面尚未取得太大进展。将hESCs转化为疗法的障碍从这些细胞在实验室中的获取和维持方式就开始了，并一直延伸到与患者特异性细胞系需求、性别特异性方面、细胞年龄以及移植后若干不确定性相关的临床并发症。简要描述了通过hESC定向分化获得并成功应用于动物疾病和损伤模型的不同类型细胞。本综述简要展望了基于hESC的疗法的现状和未来，并讨论了从实验室安全过渡到临床所需的技术进步。
